Results 41 to 50 of about 51,607 (296)

Inhibition of mTOR-dependent autophagy sensitizes leukemic cells to cytarabine-induced apoptotic death.

PLoS ONE, 2014
The present study investigated the role of autophagy, a cellular self-digestion process, in the cytotoxicity of antileukemic drug cytarabine towards human leukemic cell lines (REH, HL-60, MOLT-4) and peripheral blood mononuclear cells from leukemic ...
Mihajlo Bosnjak, Biljana Ristic, Katarina Arsikin, Aleksandar Mircic, Violeta Suzin-Zivkovic, Vladimir Perovic, Andrija Bogdanovic, Verica Paunovic, Ivanka Markovic, Vladimir Bumbasirevic, Vladimir Trajkovic, Ljubica Harhaji-Trajkovic   +11 more
doaj   +1 more source

BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study

Cancer, 2020
CXCR4 mediates the retention and survival of acute myelogenous leukemia blasts in bone marrow and contributes to their resistance to chemotherapy. The authors evaluated a combination of the high‐affinity CXCR4 antagonist BL‐8040 with high‐dose cytarabine
G. Borthakur, Y. Ofran, M. Tallman, J. Foran, G. Uy, J. Dipersio, M. Showel, A. Shimoni, A. Nagler, J. Rowe, J. Altman, Michal Abraham, A. Peled, Stephen M. Shaw, O. Bohana‐Kashtan, E. Sorani, Y. Pereg, A. Foley-Comer, G. Oberkovitz, Tzipi Lustig, Irit Glicko-Kabir, A. Aharon, Abi Vainstein-Haras, S. Kadosh, E. Samara, Ahmed Al-rawi, N. Pemmaraju, C. Bueso-Ramos, J. Cortes, M. Andreeff   +29 more
semanticscholar   +1 more source

Pharmacokinetics of multivesicular liposomal encapsulated cytarabine when administered subcutaneously in dogs

Journal of Veterinary Internal Medicine, 2020
Background Prolonged cytotoxic concentrations of cytarabine (CA) are required for maximum cytotoxicity. DepoCyt is a human liposomal cytarabine (LC) product that lasts longer in plasma and CSF compared with free CA (FC).
Irene B. Vazquez Fuster, Amanda R. Taylor, Annette N. Smith, Sue H. Duran, William R. Ravis, Shanese L. Jasper, Robert D. Arnold   +6 more
doaj   +1 more source

Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia

Clinical Cancer Research, 2020
Purpose: Cytarabine, 100–200 mg/mE+2/day, is commonly used in induction therapy of acute myelogenous leukemia (AML). Whether a higher dose of cytarabine would be more effective is unknown. Also, there is controversy whether high-dose cytarabine is better
Hui Wei, Ying Wang, R. Gale, D. Lin, Chun-lin Zhou, Bing-cheng Liu, S. Qiu, R. Gu, Yan Li, Xing-li Zhao, S. Wei, B. Gong, Kaiqi Liu, X. Gong, Yuntao Liu, Guangji Zhang, Z. Song, Yang Wang, Wei Li, Y. Mi, Jianxiang Wang   +20 more
semanticscholar   +1 more source

Sodium N-lauryl amino acids derived from silk protein can form catanionic aggregates with cytarabine as novel anti-tumor drug delivery systems

Drug Delivery, 2020
A sodium N-lauryl amino acids (shortly silk sericin surfactant, SSS) is synthesized with lauryl chloride and sericin amino acids recovered from silk industrial waste. The purpose of this study is to explore whether the sericin surfactant can be used as a
Meng Zhang, Shu-Xiang Zhao, Biao Ding, Yu-Qing Zhang   +3 more
doaj   +1 more source

MicroRNA-143 sensitizes acute myeloid leukemia cells to cytarabine via targeting ATG7- and ATG2B-dependent autophagy

Aging, 2020
Targeting autophagy holds promise to enhance chemosensitivity in acute myeloid leukemia (AML). MicroRNA-143 (miR-143) has been found to suppress autophagy, however, it is not clear whether miR-143 augments cytarabine cytotoxicity in AML.
Hao Zhang, Jian-min Kang, Ling Liu, Lulu Chen, Saisai Ren, Yanling Tao   +5 more
semanticscholar   +1 more source

A biophysical approach of cytarabine anticancer drug insights into human serum albumin and checkpoint kinase 1

Results in Chemistry, 2023
The present studies used biophysical techniques to examine the binding interaction mechanism of cytarabine anticancer drugs with human serum albumin (HSA) and checkpoint kinase 1.
Manoharan Rupavarshini, Subramani Karthikeyan, Sundaramoorthy Anandh, Anitha Ramamoorthi, Suganya Ramakrishnamurthy, Ganesan Bharanidharan, Prakasarao Aruna, Rajendiran Mangaiyarkarasi, Shanmugavel Chinnathambi, Ganesh N. Pandian, Singaravelu Ganesan   +10 more
doaj  

Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer.

Neuro-Oncology, 2019
BACKGROUND DEPOSEIN (NCT01645839) was a randomized open-label phase III study to explore the role of intrathecal chemotherapy in patients with newly diagnosed leptomeningeal metastasis (LM), a common manifestation of breast cancer.
É. Le Rhun, J. Wallet, A. Mailliez, M. Le Deley, I. Rodrigues, T. Boulanger, V. Lorgis, J. Barrière, Y. Robin, M. Weller, J. Bonneterre   +10 more
semanticscholar   +1 more source

Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment

South Asian Journal of Cancer, 2015
Acute myeloid leukemia (AML) treatment has always been a challenge to the treating physician. Continuous efforts are being made to improve treatment outcomes in AML. CPX-351 is a pharmacologic advancement in this direction.
Lalit S Raut
doaj   +1 more source

Bone marrow stromal cells reduce low-dose cytarabine-induced differentiation of acute myeloid leukemia

Frontiers in Pharmacology, 2023
Low-dose cytarabine (LDAC) is a standard therapy for elderly acute myeloid leukemia (AML) patients unfit for intensive chemotherapy. While high doses of cytarabine induce cytotoxicity, the precise mechanism of action of LDAC in AML remains elusive.
Tomislav Smoljo, Barbara Tomic, Hrvoje Lalic, Vilma Dembitz, Josip Batinic, Antonio Bedalov, Dora Visnjic   +6 more
doaj   +1 more source